10:03 AM
 | 
May 25, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FibroGen reports Phase I/II data for pamrevlumab in pancreatic cancer

FibroGen Inc. (NASDAQ:FGEN) reported data from 37 evaluable treatment-naïve patients with locally advanced, unresectable pancreatic cancer in an open-label, U.S. Phase I/II trial showing that pamrevlumab (FG-3019) plus gemcitabine and Abraxane nab-paclitaxel improved...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >